Motif Bio PLC Company Profile (LON:MTFB)

About Motif Bio PLC (LON:MTFB)

Motif Bio PLC logoMotif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP). Iclaprim exhibits potent activity against Gram-positive clinical isolates of various genera of staphylococci. It intends to build a portfolio of antibiotics by licensing drug candidates from organizations specializing in antibacterial research, and is pursuing programs in various stages of development.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: LON:MTFB
  • CUSIP: N/A
  • Web: https://www.motifbio.com/
Capitalization:
  • Market Cap: £108.44 million
  • Outstanding Shares: 262,878,000
Average Prices:
  • 50 Day Moving Avg: GBX 34.57
  • 200 Day Moving Avg: GBX 31.80
  • 52 Week Range: GBX 21.44 - GBX 53.50
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: GBX 0.02 per share
  • Price / Book: 20.63
Profitability:
  • Return on Equity: -773.10%
  • Return on Assets: -183.64%
Misc:
  • Average Volume: 1.67 million shs.
 

Frequently Asked Questions for Motif Bio PLC (LON:MTFB)

What is Motif Bio PLC's stock symbol?

Motif Bio PLC trades on the London Stock Exchange (LON) under the ticker symbol "MTFB."

Where is Motif Bio PLC's stock going? Where will Motif Bio PLC's stock price be in 2017?

5 brokers have issued 12 month price objectives for Motif Bio PLC's shares. Their predictions range from GBX 90 to GBX 110. On average, they expect Motif Bio PLC's share price to reach GBX 101.50 in the next year. View Analyst Ratings for Motif Bio PLC.

Who are some of Motif Bio PLC's key competitors?

Who are Motif Bio PLC's key executives?

Motif Bio PLC's management team includes the folowing people:

  • Graham George Lumsden, Chief Executive Officer, Executive Director
  • Robert Dickey IV, Chief Financial Officer
  • Rajesh B. Shukla, Vice President - Clinical Operations
  • Robert J. Bertoldi, Executive Director
  • David Huang M.D. Ph.D., Chief Medical Officer
  • Stephen Austin, Company Secretary
  • Richard Cecil Eversfield Morgan, Non-Executive Chairman of the Board
  • Craig T. Albanese, Non-Executive Director
  • Charlotta Ginman-Jones, Non-Executive Director
  • Jonathan E Gold, Non-Executive Director

How do I buy Motif Bio PLC stock?

Shares of Motif Bio PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Motif Bio PLC's stock price today?

One share of Motif Bio PLC stock can currently be purchased for approximately GBX 41.25.


MarketBeat Community Rating for Motif Bio PLC (LON MTFB)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  182 (Vote Outperform)
Underperform Votes:  136 (Vote Underperform)
Total Votes:  318
MarketBeat's community ratings are surveys of what our community members think about Motif Bio PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Motif Bio PLC (LON:MTFB) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: GBX 101.50
Consensus Price Target History for Motif Bio PLC (LON:MTFB)
Price Target History for Motif Bio PLC (LON:MTFB)
Analysts' Ratings History for Motif Bio PLC (LON:MTFB)
Show:
DateFirmActionRatingPrice TargetDetails
10/5/2017Peel HuntInitiated CoverageBuyGBX 106View Rating Details
10/5/2017Northland SecuritiesReiterated RatingBuyView Rating Details
10/4/2017FinnCapReiterated RatingBuyGBX 100View Rating Details
10/2/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 110View Rating Details
1/9/2017Rodman & RenshawInitiated CoverageBuyView Rating Details
11/11/2015Northland Capital PartnersReiterated RatingBuyGBX 114View Rating Details
(Data available from 10/22/2015 forward)

Earnings

Earnings History for Motif Bio PLC (LON:MTFB)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Motif Bio PLC (LON:MTFB)
Current Year EPS Consensus Estimate: $-25.11 EPS

Dividends

Dividend History for Motif Bio PLC (LON:MTFB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Motif Bio PLC (LON:MTFB)
Insider Trades by Quarter for Motif Bio PLC (LON:MTFB)
Insider Trades by Quarter for Motif Bio PLC (LON:MTFB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/5/2015Stakes III,John WilburInsiderBuy100,000GBX 60£60,000
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Motif Bio PLC (LON:MTFB)
Latest Headlines for Motif Bio PLC (LON:MTFB)
Source:
Loading headlines, please wait.

Social

Social activity is not available for this stock.

Chart

Motif Bio PLC (MTFB) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.